Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

GSK’s Witty: China Moving Rapidly To ‘No Growth’ Status

This article was originally published in PharmAsia News

Executive Summary

Despite a first-quarter slump, GSK insists its China business is moving back to underlying growth, although the firm’s CEO warns the country's overall pharma market has "slowed down dramatically" and is moving quickly to "no-growth" status.


Related Content

GSK Foresees Return To Emerging Markets Growth
China Approves First HPV Vaccine But Can GSK Secure Its Lead?


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst